Services List

Design Services for Magnetic Iron Oxide Nanoparticles Drug Delivery Systems

Magnetic iron oxide nanoparticles (IONPs) with a certain size of superparamagnetism have shown success as delivery carriers and heat-based therapies. Most of these delivery systems rely on surface-engineered cationic iron oxide nanoparticles that interact electrostatically with anionic nucleic acid drugs. Magnetic iron oxide nanoparticles have the advantages of small particle size, high biosafety, large surface curvature, high relaxation properties, superparamagnetism, and easy surface ding modification and functionalization.

Design Services for Magnetic Iron Oxide Nanoparticles Drug Delivery SystemsFig.1 Schematic representation of typical magnetic iron oxide nanoparticle structure. (Luther et al., 2020)

Our Services

CD Formulation provides design services for magnetic iron oxide nanoparticle drug delivery systems, including surface polymer modification of magnetic iron oxide nanoparticles and the selection of drug incorporation methods, as well as drug delivery system solutions to help customers better develop and optimize drug delivery routes.

Surface Polymer Modification of Magnetic Iron Oxide Nanoparticles

Design Services for Magnetic Iron Oxide Nanoparticles Drug Delivery Systems

Since magnetic iron oxide nanoparticles are surface modified to increase the hydrophilicity and biocompatibility of the particle surface before they can be used as carriers for the delivery of drugs (biomolecules, chemical drugs, radionuclides, etc.) in living organisms, CD Formulation provides surface coating materials including organic small molecules and organic macromolecular polymers that meet the following requirements: promote stability of IONPs in biological fluids and avoid interparticle agglomeration; provide active groups for IONPs, which can further couple drug molecules, targeting ligands and other functional molecules to become functional nanomaterials; and reduce the non-specific interaction between IONPs and cells.

Choice of Drug Binding Mode for Magnetic Iron Oxide Nanoparticles

Based on CD Formulation's advanced technology and extensive experience, two options are available, magnetic iron oxide nanoparticles based on non-covalent bonding and magnetic iron oxide nanoparticles based on covalent bonding. Our scientific team will develop a suitable solution based on the drug molecules provided by the customer, combined with the groups on the surface of magnetic iron oxide nanoparticles.

Advantages of Magnetic Iron Oxide Nanoparticles Drug Carrier System

  • Stability, i.e. the binding between the nanocarrier and the drug remains stable in the blood circulation, and the drug is released only when the nanocarrier system binds to the target tissue or cells.
  • The nanocarrier system should be able to couple a sufficient number of effector molecules.
  • Tolerability, i.e., the nanocarrier system must be tolerated by the organism and be immunologically inert.

About CD Formulation

CD Formulation provides integrated innovation solutions from strategy to implementation to help you increase opportunities and address challenges. Through our in-depth experience in many different industries, including consumer and technology, we bring innovative solutions and cross-industry best practices to drug development. If you have a requirement about our services, please contact us by phone or email, our colleagues will reply to you within three working days.

Reference

  1. Luther, David C., et al. Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles[J]. Advanced drug delivery reviews, 2020, 156: 188-213.

Online Inquiry

Please note: Our products and services can only be used for research purposes. Do not use in diagnostic or therapeutic procedures!

GET IN TOUCH

Enter your email here to subscribe.

Easy access to products and services you need from our library via powerful searching tools.

Copyright © 2022 CD Formulation. All Rights Reserved.